Axon Enterprise, Inc (NASDAQ:AXON) Shares Sold by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. trimmed its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 26.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,596 shares of the biotechnology company's stock after selling 1,304 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Axon Enterprise were worth $1,891,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. CX Institutional bought a new stake in shares of Axon Enterprise in the first quarter worth about $115,000. Xponance Inc. grew its position in Axon Enterprise by 3.5% in the fourth quarter. Xponance Inc. now owns 16,469 shares of the biotechnology company's stock worth $9,788,000 after acquiring an additional 560 shares in the last quarter. Brighton Jones LLC purchased a new position in Axon Enterprise in the fourth quarter worth about $480,000. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its position in Axon Enterprise by 16.2% in the fourth quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 12,200 shares of the biotechnology company's stock worth $7,251,000 after acquiring an additional 1,700 shares in the last quarter. Finally, NorthRock Partners LLC purchased a new position in Axon Enterprise in the fourth quarter worth about $555,000. 79.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on AXON shares. Barclays lifted their price target on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Craig Hallum lowered Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. Needham & Company LLC lifted their price target on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. The Goldman Sachs Group boosted their target price on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research report on Wednesday, May 14th. Finally, Bank of America boosted their target price on Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a research report on Wednesday, June 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $699.55.

Axon Enterprise Stock Up 1.4%

NASDAQ:AXON traded up $11.01 during trading hours on Tuesday, reaching $794.25. The company's stock had a trading volume of 743,378 shares, compared to its average volume of 533,953. The company has a market capitalization of $61.83 billion, a P/E ratio of 191.85, a price-to-earnings-growth ratio of 90.16 and a beta of 1.29. Axon Enterprise, Inc has a 12 month low of $279.02 and a 12 month high of $806.64. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.62 and a current ratio of 2.83. The stock has a 50 day moving average price of $700.64 and a two-hundred day moving average price of $627.10.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The company had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. Axon Enterprise's revenue for the quarter was up 31.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.15 earnings per share. Equities analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CAO Jennifer H. Mak sold 75 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $771.81, for a total transaction of $57,885.75. Following the transaction, the chief accounting officer now directly owns 15,240 shares of the company's stock, valued at approximately $11,762,384.40. This represents a 0.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, President Joshua Isner sold 905 shares of the company's stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $776.39, for a total value of $702,632.95. Following the transaction, the president now directly owns 268,735 shares in the company, valued at approximately $208,643,166.65. The trade was a 0.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 44,642 shares of company stock valued at $30,500,428 over the last 90 days. Corporate insiders own 5.70% of the company's stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.